GleamWall
中文EN

GRML Greenland Mines Ltd

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1907223 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-199.9%
TTM EPS YoY109.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-44.3%
ROA-44.0%
ROIC (approx.)-56.3%
Asset turnover—

Leverage & solvency

Liabilities / assets1.0%
Debt / equity0.00x
Current ratio62.16x
Interest coverage25.06x

Cash quality & payout

Operating cash flow / net income0.72x
Accruals ratio-12.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$409,521$400,536$321,271$124,342$273,305$238,700$0$0
SG&A expense$1.47M$577,942$6.21M$862,966$868,830$729,572$850,282$2.72M
Operating income-$12.41M-$5.49M-$9.51M-$1.81M-$1.85M-$1.89M-$1.59M-$1.85M
Interest expense$4,950$4,888$1,615-$1.18M$1.18M$1.76M$553,937$296,583
Pretax income-$13.64M-$3.69M-$13.86M-$1.33M-$2.90M-$4.09M-$2.12M-$2.07M
Income tax$0———$0———
Net income-$13.64M-$3.69M-$13.86M-$1.33M-$2.90M-$3.76M-$2.12M-$2.07M
EBITDA-$12.40M———-$1.85M———
EPS (basic)-2.51-0.03-0.15—-2.39-0.12-0.08—
EPS (diluted)-2.51-0.03-0.15—-2.39-0.12-0.08—
Weighted avg. shares (diluted)5.44M126.52M93.73M—1.21M33.95M27.52M—
Balance sheet
Cash & equivalents$57.39M$9.30M$10.00M$7.18M$7.35M$8.43M$565,869$63,741
Receivables————$339,253———
Current assets$59.46M$12.21M$10.93M$7.29M$7.77M$8.55M$687,712$157,811
PP&E, net$440,457$317,530—$0————
Intangibles$74.11M$48.67M$48.67M$2.30M————
Total assets$137.69M$65.01M$59.74M$9.59M$10.07M$10.85M$2.99M$2.46M
Current liabilities$956,582$1.21M$553,739$76,764$92,891$62,962$2.34M$1.25M
Total liabilities$1.35M$7.11M$8.27M$129,764$145,891$195,409$2.35M$1.27M
Shareholders' equity$136.35M$57.90M$51.47M$9.46M$10.38M$11.10M$755,965$1.19M
Shares outstanding13.69M3.24M121.24M1.48M70.33M52.70M28.51M27.08M
Cash flow statement
Operating cash flow-$10.41M-$6.85M-$4.97M-$1.28M-$1.09M-$1.97M-$1.55M-$944,154
Capital expenditure$133,915———————
Free cash flow-$10.54M———————
Investing cash flow-$20.13M-$428,680-$365,324————$0
Financing cash flow$78.58M$6.62M$8.16M$1.11M$5,300$9.83M$2.06M$957,000
Depreciation & amortization$10,988———$0———
Stock-based compensation$907,375$111,083$5.11M$39,931$639,586$390,195$495,500$659,207

Free plan shows the latest 8 periods; Pro shows all 22 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.